Here’s Why Abbott Laboratories (ABT) Traded Down in Q3

4 days ago 2

Soumya Eswaran

Wed, November 12, 2025 astatine 8:10 AM CST 2 min read

Carillon Tower Advisers, an concern absorption company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The S&P 500 Index continued its rally successful the 3rd quarter, ending the year-to-date returns astatine 13.7%. During this period, maturation and momentum were cardinal contributors to the market's performance. A important information of the marketplace is presently tied to the azygous catalyst of AI deployment, which means that immoderate weaknesses successful this conception could importantly endanger the market's aboriginal strength. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Carillon Eagle Growth & Income Fund highlighted stocks specified arsenic Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is simply a starring shaper of wellness attraction products. The one-month instrumentality of Abbott Laboratories (NYSE:ABT) was -1.89%, and its shares mislaid 9.73% of their worth implicit the past 52 weeks. On November 11, 2025, Abbott Laboratories (NYSE:ABT) banal closed astatine $127.00 per share, with a marketplace capitalization of $220.837 billion.

Carillon Eagle Growth & Income Fund stated the pursuing regarding Abbott Laboratories (NYSE:ABT) successful its 3rd 4th 2025 capitalist letter:

"Abbott Laboratories (NYSE:ABT) underperformed successful the 3rd quarter, mostly owed to disappointing second-quarter fiscal results and a downward revision of its fiscal guidance. While astir concern segments are performing well, the company’s diagnostics conception is facing challenges successful China, driven by brushed economical conditions and authorities unit connected aesculapian merchandise pricing."

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Abbott Laboratories (NYSE:ABT) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 69 hedge money portfolios held Abbott Laboratories (NYSE:ABT) astatine the extremity of the 2nd quarter, compared to 70 successful the erstwhile quarter. While we admit the imaginable of Abbott Laboratories (NYSE:ABT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the database of champion dividend aristocrat stocks to put in. In addition, delight cheque retired our hedge money capitalist letters Q3 2025 page for much capitalist letters from hedge funds and different starring investors.